ASR Vermogensbeheer N.V. Sells 355 Shares of Humana Inc. $HUM

ASR Vermogensbeheer N.V. trimmed its position in Humana Inc. (NYSE:HUM) by 2.5% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 13,886 shares of the insurance provider’s stock after selling 355 shares during the period. ASR Vermogensbeheer N.V.’s holdings in Humana were worth $3,395,000 at the end of the most recent reporting period.

Several other large investors have also recently bought and sold shares of the company. Revolve Wealth Partners LLC bought a new stake in Humana during the fourth quarter valued at $202,000. Merit Financial Group LLC boosted its position in shares of Humana by 343.0% during the 1st quarter. Merit Financial Group LLC now owns 8,058 shares of the insurance provider’s stock valued at $2,132,000 after acquiring an additional 6,239 shares during the last quarter. Riverview Trust Co bought a new stake in shares of Humana during the 1st quarter valued at about $34,000. Gateway Investment Advisers LLC boosted its position in shares of Humana by 53.4% during the 1st quarter. Gateway Investment Advisers LLC now owns 3,629 shares of the insurance provider’s stock valued at $960,000 after acquiring an additional 1,263 shares during the last quarter. Finally, Sivia Capital Partners LLC bought a new stake in Humana during the first quarter valued at approximately $223,000. 92.38% of the stock is owned by institutional investors.

Humana Price Performance

Shares of NYSE:HUM opened at $284.00 on Friday. The stock has a market cap of $34.16 billion, a PE ratio of 21.80, a PEG ratio of 1.51 and a beta of 0.42. The company’s fifty day moving average is $274.76 and its 200 day moving average is $257.42. The company has a quick ratio of 1.95, a current ratio of 1.95 and a debt-to-equity ratio of 0.69. Humana Inc. has a 52 week low of $206.87 and a 52 week high of $315.35.

Humana (NYSE:HUM) last released its quarterly earnings data on Wednesday, July 30th. The insurance provider reported $6.27 EPS for the quarter, missing the consensus estimate of $6.32 by ($0.05). The company had revenue of $32.39 billion during the quarter, compared to analysts’ expectations of $31.85 billion. Humana had a return on equity of 13.67% and a net margin of 1.28%.The firm’s quarterly revenue was up 9.6% on a year-over-year basis. During the same quarter in the prior year, the firm posted $6.96 EPS. Humana has set its FY 2025 guidance at 17.000- EPS. Research analysts anticipate that Humana Inc. will post 16.47 earnings per share for the current year.

Humana Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, October 31st. Investors of record on Friday, September 26th will be paid a $0.885 dividend. This represents a $3.54 annualized dividend and a dividend yield of 1.2%. The ex-dividend date of this dividend is Friday, September 26th. Humana’s payout ratio is presently 27.17%.

Wall Street Analyst Weigh In

HUM has been the subject of several research analyst reports. Wall Street Zen lowered shares of Humana from a “buy” rating to a “hold” rating in a research report on Saturday, August 2nd. Bank of America lifted their price objective on shares of Humana from $285.00 to $312.00 and gave the stock a “neutral” rating in a report on Tuesday, September 2nd. Morgan Stanley lowered their price target on Humana from $290.00 to $277.00 and set an “equal weight” rating on the stock in a research report on Thursday, July 31st. Mizuho set a $300.00 price target on Humana in a research report on Friday. Finally, Wells Fargo & Company lowered their price target on Humana from $348.00 to $344.00 and set an “overweight” rating on the stock in a research report on Thursday, August 14th. Seven analysts have rated the stock with a Buy rating, thirteen have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Humana currently has an average rating of “Hold” and a consensus target price of $291.21.

Humana Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.